Illumina v. FTC

Track this case

Case overview

Case Number:

23-60167

Court:

Appellate - 5th Circuit

Nature of Suit:

Agency 

Companies

Government Agencies

Sectors & Industries:

  1. June 06, 2023

    Illumina Tells 5th Circ. Grail Case 'Flagrant' Overreach

    Illumina told the Fifth Circuit that the Federal Trade Commission's case challenging its $8 billion repurchase of cancer testing company Grail is "flagrant" overreach that is costing lives and highlights constitutional problems with the agency.

  2. June 01, 2023

    FTC Wants 5th Circ. To Slow Down Illumina's Grail Appeal

    The Federal Trade Commission has told the Fifth Circuit there's no need to expedite Illumina's appeal in the agency's case challenging the DNA sequencing giant's acquisition of cancer-testing company Grail and asked to delay the slated August argument.

  3. May 08, 2023

    Illumina Tells Shareholders Icahn Wrong About Selling Grail

    Illumina is continuing to urge shareholders to reject Carl Icahn's board nominees, saying in a letter Monday the activist investor's sole argument for a shakeup is based on the "false belief" that his nominees will be able to push for a fast sale of cancer testing outfit Grail.

  4. April 25, 2023

    FTC Pauses Illumina-Grail Order Amid 5th Circ. Appeal

    The Federal Trade Commission paused an order on Monday that would prevent biotech company Illumina from fully combining with cancer test maker Grail while the businesses appeal the agency's decision to unwind the merger.

  5. April 19, 2023

    5th Circ. Fast-Tracks Illumina's Grail Appeal

    A Fifth Circuit panel has agreed to expedite Illumina's appeal as the DNA sequencing giant fights a Federal Trade Commission decision ordering the unwinding of its deal for cancer-test developer Grail.

  6. April 17, 2023

    Illumina Pushes FTC For Full Pause Of Grail Order

    Illumina told the Federal Trade Commission that barring it from integrating with cancer screening outfit Grail Inc. while it appeals the agency's decision finding the acquisition violates antitrust law is unnecessary and could delay access to life-saving cancer tests.

  7. April 13, 2023

    FTC Staff Say Full Pause Of Illumina Order Too Risky

    Federal Trade Commission staffers urged the commissioners to ensure Illumina remains separate from Grail Inc. while the company appeals an order to unwind their merger, arguing that keeping their operations apart will spur competition from rival cancer tests.

  8. April 05, 2023

    Illumina To Appeal FTC's Grail Unwinding To 5th Circ.

    Illumina Inc. lodged an intent to appeal Wednesday with the Fifth Circuit as it fights a Federal Trade Commission order calling for the DNA sequencing provider to unwind its $8 billion reacquisition of cancer-testing outfit Grail Inc. and asked the court to move quickly.